Trending: Eisai/Biogen Alzheimer's Drug Shows Positive Results
November 30 2022 - 10:46AM
Dow Jones News
10:16 ET -- Eisai Co. and Biogen Inc. are among the most talked
about companies in the U.S. across all news items in the last 12
hours, according to Factiva data. A study of the companies'
closely-watched lecanemab candidate for Alzheimer's disease showed
the drug slowed cognitive decline by 27% compared with a placebo
over 18 months but was associated with swelling and bleeding in the
brain, with researchers recommending further, longer study. Dow
Jones & Co. owns Factiva. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
November 30, 2022 10:31 ET (15:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024